Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.
Also called NCT01726816
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 126 participants
- Registry
-
NCT01726816
-
- Other papers using this trial's data
- Probucol in Albuminuric Type 2 Diabetes Mellitus Patients on Renin-Angiotensin System Blockade: A 16-Week, Randomized, Double-Blind, Placebo-Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT01726816. Randomized; double masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy
- Condition
- Diabetic Nephropathy
- Intervention (Drug)
- Probucol 250mg/day
- Intervention (Drug)
- Probucol 500mg/day
- Intervention (Drug)
- Placebo
- Lead sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Record details
- Record id
cardio:ct-nct01726816- Content hash
ac15c7b7313d4411aefeee4bfa1675cdb07e3e50556966dd7eb6b6dda5acaf17